Artrya’s Half-Year Loss Widens Despite Strong Rise in Net Tangible Assets

Artrya Limited ( (AU:AYA) ) has issued an update.

Artrya Limited reported a significant increase in its half-year loss for the six months to 31 December 2025, with the loss after tax attributable to owners widening 44.4% to $10.743 million from $7.441 million a year earlier. The company did not declare or pay any dividends for the period, but disclosed a sharp improvement in net tangible assets per share, which rose to 53.67 cents at 31 December 2025 from 14.61 cents at 30 June 2025, a move that may reflect capital restructuring or asset revaluation and is likely to draw close scrutiny from investors assessing the company’s financial trajectory.

The interim financial statements for the half-year were reviewed by the company’s auditors, with the review report included in the interim financial report. The absence of any noted audit dispute or qualification provides some reassurance on the reliability of the reported figures, even as the larger loss underscores the ongoing cost pressures and investment needs typical of growth-focused medtech businesses still working toward sustainable profitability.

The most recent analyst rating on (AU:AYA) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.

More about Artrya Limited

Artrya Limited is an Australian-listed company operating in the healthcare and medical technology sector. The company focuses on developing and commercialising advanced diagnostic solutions, with an emphasis on imaging-based technologies aimed at improving cardiovascular care and related clinical decision-making.

Average Trading Volume: 624,576

Technical Sentiment Signal: Buy

Current Market Cap: A$485.3M

For a thorough assessment of AYA stock, go to TipRanks’ Stock Analysis page.